CD123 and CD200 as markers for the diagnosis and immuneradication of leukemia stem cells (LSC)

JP2025522555A5Pending Publication Date: 2026-05-29F HOFFMANN LA ROCHE & CO AG +1
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
F HOFFMANN LA ROCHE & CO AG
Filing Date
2023-06-21
Publication Date
2026-05-29

AI Technical Summary

Technical Problem

Current treatments for acute myeloid leukemia (AML) face challenges in targeting leukemia stem cells (LSCs) due to the lack of specific antigens and high similarity to healthy hematopoietic stem cells, leading to chemotherapy resistance and relapse, with existing targets causing off-target toxicity and immune evasion.

Method used

Development of bispecific antigen-binding molecules that target both CD123 and CD200 proteins, which are co-expressed in LSCs, using a trifab-contosobody format to selectively bind and activate T cells, thereby enhancing immunotherapy efficacy.

Benefits of technology

The bispecific antigen-binding molecules provide selective cytotoxicity against LSCs, reducing off-target effects and improving treatment outcomes by activating T cells only when both CD123 and CD200 are expressed, thus enhancing therapeutic efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000025_0000
    Figure 00000025_0000
  • Figure 00000025_0001
    Figure 00000025_0001
  • Figure 00000025_0002
    Figure 00000025_0002
Patent Text Reader

Abstract

The present invention relates to an antigen-binding molecule that is at least bispecific for and specifically binds to CD200 and CD123 on the cell surface of leukemia stem cells (LSCs). The present invention further relates to a method for identifying such an antigen-binding molecule, and to the use of the antigen-binding molecule for the diagnosis and treatment of leukemia such as AML or CML, particularly their pediatric forms.
Need to check novelty before this filing date? Find Prior Art